期刊
EXPERT REVIEW OF HEMATOLOGY
卷 6, 期 5, 页码 611-624出版社
TAYLOR & FRANCIS LTD
DOI: 10.1586/17474086.2013.840997
关键词
azacitidine; decitabine; hematopoietic growth factors; hematopoietic stem cell transplant; hypomethylating agents; lenalidomide; myelodysplastic syndromes
类别
Several classification and scoring systems have been developed in myelodysplastic syndromes (MDS to predict the risk of progression to acute myeloid leukemia and survival. These prognostication models have been also used to inform therapeutic decision-making in a risk-adapted fashion. Patient-related factors such as age, comorbidities, and functional status have to be considered as well. Here we review a risk-guided therapeutic approach for the management of MDS patients. It is anticipated that the improved understanding of the complex pathogenesis of MDS and the recent discovery of important molecular lesions will be translated into novel therapeutic approaches. Additionally, some prognostic aberrations are expected to be incorporated into the prognostic tools with the goal of improving their prognostic precision and therefore allow for a more informed therapeutic decision-making based on the individual's risk profile.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据